Press releases
The Board of Directors of DexTech proposes a rights issue of approx. MSEK 58.2 in order to further develop the project with multiple myeloma to clinical research and further verify OsteoDex’s value
8 November, 2021The Board of Directors of DexTech Medical AB (“DexTech” or the “Company”) has today decided to convene an Extraordinary General Meeting on November 25, 2021, with a proposal for a […]
Invitation to open Annual General Meeting and notice
28 October, 2021On Thursday, November 25, 2021, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]
Interim report July 1, 2021 – September 30, 2021
22 October, 2021Summary of the First Quarter (2021-07-01 – 2021-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -0,9 (-1,5) • Earnings per share* SEK -0,06 […]
DexTech strengthens board ahead of myeloma study
7 October, 2021DexTech strengthens board ahead of myeloma study DexTech Medical AB (“DexTech”) intends, as previously communicated, to conduct a clinical proof of concept study regarding the company’s main candidate OsteoDex (ODX) […]
Dextech Medical AB Annual report 200701 – 210630
28 September, 2021Download annual report below. DexTech Medical AB Annual report 200701-210630
Year-end report July 1, 2020 – June 30, 2021
30 August, 2021Summary of the Fourth Quarter (April 1 – June 30, 2021) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -1,5 (-1,9) • Earnings per […]
DexTech is planning a new clinical study on multiple myeloma
24 August, 2021DexTech announces that OsteoDex ́ (ODX) pre-clinical results regarding the effect on multiple myeloma (MM) are so convincing that the company now plans a clinical “proof of concept study” (short […]
DexTech confirms very positive results from myeloma studies
10 May, 2021At the beginning of the year, the company announced positive results from initial in vitro studies regarding OsteoDex (ODX) effect on multiple myeloma (MM). MM is a form of blood […]
Interim report July 1, 2020 – March 31, 2021
20 April, 2021Summary of the Nine-Month period (2019-07-01 – 2020-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -4,6 (-5,8) Earnings per share * SEK -0.31 (-0.39) Cash […]
Half Year report July 1 – December 31, 2020
2 February, 2021Summary of the First Half Year (2020-07-01 – 2020-12-31) • Net sales amounted to MSEK 0.0 (0.0) • Operating profit/loss amounted to MSEK -3.1 (-3.9) • Earnings per share * […]